Prevalence, patterns, and impacts of multimorbidity on adverse clinical outcomes in chronic kidney disease: A systematic review

Samin Chowdhury, NIHR Academic Clinical Fellow General Practice, Lancaster Medical School

ABSTRACT

Background: Multimorbidity is the concurrent presence of two or more long-term health conditions in the same individual. It fragments healthcare delivery and affects quality of life. Chronic kidney disease (CKD) often occurs with multimorbidity. The prevalence of CKD is rising; however, there is a lack of evidence on the prevalence, patterns, and impacts of multimorbidity on adverse clinical outcomes in patients with CKD.

Methods: This was a systematically conducted literature review. A search was conducted in EMBASE, MEDLINE, CINAHL, and SCOPUS (2019-2023). The main search terms were “chronic kidney disease” and “multimorbidity.” The eligibility criteria were observational studies with adult participants with all stages of CKD (CKD stages 1-5, including those on renal replacement therapy). The exposure was multimorbidity quantified by measures. All-cause mortality, kidney disease progression, hospitalisation, and cardiovascular events were outcomes. The Joanna Briggs Institute (JBI) checklist was used for the risk of bias assessment. Due to heterogeneity in design and methods, Jennie Popay’s narrative synthesis was used for data synthesis.

Results: Of 6879 papers, nine papers met the inclusion criteria. Most studies included participants with all stages of CKD (CKD stage 1-5). The prevalence of multimorbidity ranged from 86.6% to 99.1%. Hypertension was the most prevalent comorbidity. The combination of concordant multimorbidity (hypertension, diabetes, and cardiovascular diseases) was highly prevalent. Multimorbidity was significantly associated with mortality, cardiovascular events, kidney disease progression, and hospitalisation. While older people had more multimorbidity burdens, younger patients with CKD were at a higher risk of death from multimorbidity. Severe CKD with clusters of cardiovascular diseases, diabetes, chronic pain, and depression was significantly associated with all-cause mortality.

Conclusion: There are associations between multimorbidity and adverse clinical outcomes in patients with CKD. However, there is a lack of data on Black, Asian, and Minority Ethnic participants from low- and middle-income countries. Further research is needed to investigate the high prevalence of chronic pain and depression in chronic kidney disease.

BACKGROUND

Multimorbidity is having two or more long-term health conditions (LTCs) simultaneously in the same person.1 With the advent of modern medicine, more people are living longer, thereby developing multimorbidity.2 A recent systematic review reported that the global age-adjusted prevalence of multimorbidity is approximately 37.2%.3 Multimorbidity affects approximately 50 million people in the European Union.4 It is also becoming more common in lower and middle-income countries (LMICs).4-7 In England and Scotland, 27.2% and 23.2% of people have multimorbidity.5,6 Multimorbidity affects life expectancy, the amount of treatment needed, daily function, and quality of life. It makes healthcare delivery more complicated and makes it harder to coordinate care. People with multimorbidity use health services more than those with only one health condition. Therefore, the Academy of Medical Sciences (AMS) and the National Institute for Health and Care Research (NIHR) identified multimorbidity as a priority area of research.4,7

Chronic kidney disease (CKD) is a progressive loss of kidney function or damage to the structure of the kidney lasting for at least three months.8 It affects approximately 10% of the global population and is often linked to multimorbidity.9,10 It has five stages based on the range of kidney function measured by estimated glomerular filtration rate (eGFR). People with chronic kidney disease have the highest death rate of anyone with a long-term health condition.11,12 CKD patients also need more hospital admission than those without.13 Multimorbidity makes it more likely that kidney function will worsen, leading to the need for dialysis, kidney transplants, and higher healthcare costs.11,12,13 Therefore, Kidney Research UK has recently identified the need to investigate the link between multimorbidity and CKD.14

To improve patient outcomes, it is becoming more apparent how important it is to determine how common and “clustered” multiple health conditions are.7 When a person has multiple health conditions, health guidelines and care usually focus on treating each condition separately. This disjointed way of giving care does not always meet the complex needs of people with multimorbidity. For example, guidelines do not consider how different medicines interact or how severe each health condition is in a person with multimorbidity.16,17 People with CKD often have heart disease and diabetes, examples of “concordant multimorbidity”. This means conditions with the exact cause and disease pathways.11,20,21 They also have health problems that are not directly linked to CKD, such as mental health problems, including depression (“discordant multimorbidity”).22,23 Therefore, finding these “clusters” of conditions is essential so that early, focused interventions can be made to improve clinical outcomes.24,25

Whilst Sullivan et al. (2020) published a similar systematic review to assess the impacts of multimorbidity on mortality in patients with CKD stages 3-5, there is a lack of evidence on how patterns or clusters of multimorbidity in all-stage CKD (including mild-moderate CKD) affect other important clinical outcomes.26 Therefore, this study aims to examine the current research to determine the prevalence and patterns of multimorbidity in all-stage CKD. The study also aims to determine how multimorbidity is linked to adverse clinical outcomes in people with all-stage CKD.

METHODS

A systematically conducted literature review. The guidance on conducting systematic reviews and meta-analyses of observational studies of etiology (COSMOS-E) was followed to conduct this review.37 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed for reporting (see additional file appendix 6).38 The review was not registered with the International Prospective Register of Systematic Reviews (PROSPERO).
Research questions
1. What are the prevalence and patterns of multimorbidity in adult patients with chronic kidney disease (CKD)?
2. How does multimorbidity affect clinical outcomes in adult patients with chronic kidney disease (CKD)?

Objectives
- Determine the prevalence and patterns of multimorbidity in patients with any stage of CKD to understand the extent and “clusters” of multimorbidity associated with CKD.
- Investigate the association between multimorbidity and adverse clinical outcomes in patients with CKD to understand the impact. This will help develop targeted clinical interventions.

Design
A systematic review without meta-analysis.

Inclusion criteria
- Studies investigating the prevalence or patterns of multimorbidity in CKD or reduced renal function (estimated glomerular filtration rate <90 ml/min/1.73 m²). Any multimorbidity measures were accepted, including simple counts or a comorbidity scoring system.
- Studies that investigated the association between multimorbidity and adverse clinical outcomes in patients with CKD. Outcomes were hospitalisation, mortality, cardiovascular events including myocardial infarction or stroke, progression of CKD to kidney failure or renal replacement therapy, and association of multimorbidity with CKD severity.
- Studies that counted CKD as a multimorbidity.
- Adult participants aged 18 and over.
- Studies published in English.

Exclusion criteria
- Qualitative studies as the outcomes studied are quantitative in nature.
- Narrative or systematic reviews.
- Drug intervention studies.
- Randomised controlled trials as they often exclude multimorbidity participants.
- Case reports or conference abstracts.
- Studies with children or adolescents below 18. Kidney functions differ between adults and children.
- Animal or other experimental preclinical studies.

Data synthesis
The general framework of the narrative synthesis by Popay et al. (2006) was used. This is because considerable heterogeneity was observed in the included studies regarding methods, sample size, study designs, and outcomes. 29

Quality assessment
The studies included were either cross-sectional or cohort studies. Based on this, the methodological quality of the included studies was assessed using the Joanna Briggs Institute (JBI) critical appraisal checklist for cross-sectional and cohort studies. The JBI tool has eight questions for cross-sectional studies and 11 for cohort studies to assess the risk of bias in a study’s design, conduct, and analysis. 29 Based on subjective scoring, studies were rated high, moderate, and low quality. Studies were not excluded based on the quality appraisal. The overall quality of the review was assessed using the SANRA (a scale of the quality assessment of the narrative review articles) checklist. 29

Patient and public involvement
No patient or the public was involved.

RESULTS

Search results
The search retrieved 6879 papers. After deduplication, the titles and abstracts of 5229 articles were screened, and 11 papers were included. After the full-text screening, two of these 11 papers were excluded because they were conference abstracts. Therefore, nine articles were included in the final analysis.

Six studies were prospective cohorts, and three were cross-sectional. The sample size of the included studies ranged between 252 and 892,005. Most of the studies were conducted in Europe and the USA. Seven studies examined patients with CKD stages 3-5 who were not on dialysis. Six of them included patients with mild-moderate CKD (CKD stage 1-3, eGFR ≥30 ml/min/1.73 m²). 25-27 Four studies included patients without CKD. Only one study involved patients on renal replacement therapy, including dialysis. 28 Except for Sullivan et al. (2021), all the studies measured multimorbidity by simply counting them (“condition count”). 25-40

Prevalence of multimorbidity in CKD
The prevalence of multimorbidity, including CKD, was higher in most studies, ranging from 86.6% to nearly 99.1%, as reported by five studies. 24, 25, 27, 29, 30, 40 When CKD was excluded, the prevalence of two or more comorbidities was reported at 25%-57.3% by three studies. 24, 25, 30, 40 Both Pato et al. and Sullivan et al. (2022) reported a higher number of comorbidities in more severe CKD (CKD stages 4 and 5) than in mild to moderate CKD (CKD 1-3). 25, 47 As reported by three studies, older patients with CKD had a higher multimorbidity burden than the younger population. 26, 36, 38 Only three studies collected data from the Black, Asian, and Minority Ethnic (BAME) populations. 24, 34, 39

Multimorbidity patterns
Hypertension was the most prevalent comorbidity, as reported by seven studies. 25, 26, 27, 29, 30 The combination of hypertension, diabetes, and cardiovascular diseases was highly prevalent in three studies. 25, 27, 29

Outcomes
Multimorbidity was significantly associated with mortality, major adverse cardiovascular and kidney events, and hospitalisation. 25, 27, 38 While older people had more multimorbidity burdens, younger patients with CKD were at a higher risk of death from multimorbidity. 25, 38 Severe CKD (eGFR <30 ml/min/1.73 m²) with clusters of heart failure,
Prevalence, patterns, and impacts of multimorbidity on adverse clinical outcomes in chronic kidney disease: A systematic review

Samin Chowdhury

peripheral vascular disease, atrial fibrillation, diabetes, chronic pain, and depression were significantly associated with all-cause mortality and major cardiovascular events.20

C. Assessing the robustness of the synthesis.

All cohort studies were of good quality with a low risk of bias. Two were at risk of selection bias, as they did not describe the loss to follow-up in adequate detail. In contrast, more than half of the cross-sectional studies had a moderate to high risk of selection and misclassification bias.

DISCUSSION

The study shows that CKD patients have a high rate of multimorbidity. This is similar to a recent systematic review examining adverse outcomes for CKD patients with multimorbidity.21 The literature shows that some diseases, such as high blood pressure, diabetes, and heart disease, are very common in people with CKD. Several studies have reported that complications of CKD, such as mineral malabsorption, oxidative stress, and chronic inflammation, can cause this clustering.22 This study also shows that multimorbidity is strongly linked to mortality, hospitalisation, and major cardiovascular events. This is not an unexpected finding. There is well-established evidence that these conditions are linked in the disease pathways and have poor outcomes.23 This group may benefit from an integrated clinic that can meet their complex medical needs. Integrated clinics have been shown to help people with CKD by reducing high blood pressure, high cholesterol, and high blood sugar.24

This review shows that multimorbidity is strongly linked to reduced kidney function. It is also linked to the progression of CKD to kidney failure that needs dialysis or a kidney transplant. This result is similar to an earlier systematic review that showed that multimorbidity was associated with the progression of CKD to dialysis.25 This shows the importance of frequent monitoring of kidney function in this cohort of patients.

The review showed that depression and chronic pain, which are discordant multimorbidities, are linked to more advanced CKD (stages 4 and 5) (eGFR<30 ml/min/1.73 m²). This is similar to other studies that showed that depression is common in people with advanced CKD. However, it is often misdiagnosed and undertreated.26 Depression in people with CKD makes it harder for them to take medicines. Moreover, antidepressants work less well with reduced kidney function. A systematic review found that depression-focused interventions were the most effective in multimorbidity.27 These goal-based interventions might be useful for people with both CKD and depression. However, there is a lack of evidence on why chronic pain is so common in CKD.28 29

The strength of the review lies in the robustness of its methodology. The process of selecting the studies was transparent. Both individual papers and the review itself were judged using well-validated appraisal checklists.

In 2020, a systematic review was performed to examine the adverse outcomes of multimorbidity in people with chronic kidney disease.30 To the best of the author's knowledge, this is the first study since the review was published to look at the trends of multimorbidity and its associated adverse outcomes in people with CKD. In their systematic review, Sullivan et al. (2020) said that there was not enough data to determine how patients with mild-to-moderate CKD (eGFR>30 ml/min/1.73 m²) would fare if they had multimorbidity.31 Almost all the studies in this review looked at people with mild to moderate CKD, and one study also looked at people who had kidney transplants.32 However, this study has some limitations. Over half of the studies were cross-sectional. This made it harder to explore the longitudinal change in multimorbidity patterns. Additionally, in a few studies, there was a risk of selection bias because people self-reported their multimorbidity.33 Some studies used a single test of eGFR to define CKD without measuring it after three months, making the exposure inadequate.34 35 There was not enough information about people who dropped out of the study. All the studies used health databases to collect data; however, a few did not provide a reference for the diagnostic codes used, which might have introduced misclassification bias.36

It is well known that people from BAME groups are more likely to develop CKD. They also disproportionately suffer CKD-related diseases such as diabetes and high blood pressure.37 38 Nevertheless, most of the people in almost all studies were white. CKD affects more people in lower- and middle-income countries than high-income countries.39 However, eight of the studies in this review were conducted in countries with high incomes, which makes it difficult to generalise the results. It would be helpful to see how the severity of different comorbidities affects the results. However, none of the studies looked at this link, which could be an important confounder.40

CONCLUSIONS

This study shows that people with all stages of CKD are more likely to have multimorbidity. Older CKD patients tend to have a higher number of comorbidities. Younger people with CKD can also have multiple health problems, making them more likely to die than older people. High blood pressure, diabetes, and heart conditions often occur together with CKD. These "clusters" are also linked to poor clinical outcomes, such as hospital admission and mortality. The review provides evidence that depression and chronic pain, which seem to have nothing to do with CKD, often coexist.

Recommendations for future research

For future studies to have more generalisable results, they should include more BAME participants. More research needs to be done to investigate the link between CKD and discordant multimorbidity. To date, most studies have investigated the effects of multimorbidity on clinician-centred outcomes. In future studies, multimorbidity should be examined in terms of patient-focused outcomes. This includes quality of life, disease burden, fatigue, and insomnia. Patients with CKD and multimorbidity are often excluded from randomised controlled studies; therefore, CKD patients with multimorbidity need more pragmatic controlled trials using large databases. This should reduce selection bias and improve the generalisability of the results. Lastly, lower and middle-income countries should conduct more research in this area. This will help them understand the pattern and outcomes of multimorbidity in CKD. This will help these countries make decisions about treatment and healthcare policy.

Correspondence to:
s.s.chowdhury@lancaster.ac.uk

(REFERENCES AND SUPPLEMENTARY FILES ARE AVAILABLE ON REQUEST)